The Interaction of Nepafenac and Prostaglandin Analogs in Primary Open-angle Glaucoma Patients

Abstract

Purpose: To investigate the effect of nepafenac on intraocular pressure (IOP) in primary open-angle glaucoma (POAG) patients treated with prostaglandin (PG) analogs. Materials and Methods: This prospective clinical study included 35 patients who had been receiving latanoprost (n = 12), travoprost (n = 12), or bimatoprost (n = 11) for POAG. Nepafenac 0.1% and placebo drops were administered to the right and left eyes of patients, respectively, 3 times a day for 7 days. IOP measurements were taken at 9: 00 AM, 12: 00 PM, and 4: 00 PM at baseline and all consecutive visits. The visits were scheduled on days 1 and 7 during treatment and 1 and 7 days after discontinuation of the treatment. Results: The mean age of the patients was 60.28 +/- 7.51 years (range, 48 to 75 y). The baseline IOP was similar in the nepafenac and placebo groups (15.33 +/- 1.45 vs. 15.41 +/- 1.41, respectively, P > 0.05). The decrease in the mean IOP was significant in the nepafenac group compared with the placebo group throughout the treatment period (P < 0.001). After the discontinuation of nepafenac treatment, the mean IOP became similar with the placebo group from the first day (P > 0.05). The change in mean IOP was not significant between the PG subgroups during treatment and discontinuation periods (P = 0.712). Conclusions: Nepafenac potentiates the IOP-lowering effects of 3 different PG analogs in POAG patients.